Primary study · included by 1 review
Reproductive and hormonal factors and bladder cancer risk: a prospective study and meta-analysis.
Xu 2020 · Xu Xin, Mo Qiwang, Shen Haixiang, et al. · Aging · 2020
Included by
| Outcome this study informs | Pooled effect | Evidence | Certainty |
|---|---|---|---|
Risk of bladder cancer With sodium-glucose transporter-2 inhibitors vs Without sodium-glucose transporter-2 inhibitors | RR 0.93 [0.71, 1.21] | 6 studies · 87218 participants | Moderate |
Risk of bladder cancer ABO blood group AB vs ABO blood group O | HR 1.06 [0.95, 1.19] | 5 studies · 1946008 participants | Very low |
Risk of bladder cancer Early menopause vs Non-menopause | RR 1.22 [1.06, 1.40] | 7 studies | Very low |
Risk of bladder cancer With estrogen-progestogen therapy for hormone replacement therapy vs Without estrogen-progestogen therapy for hormone replacement therapy | RR 0.79 [0.59, 1.06] | 5 studies | Very low |
1 including review in total.